Illumina 관리 팀

Steve Barnard, PhD는 Illumina의 최고 기술 책임자입니다. 그는 엔지니어링, 소모품, 애플리케이션, 사용자 디자인, 소프트웨어, 인포매틱스, 인공 지능, 과학 업무 및 글로벌 고급 과학 분야에서 Illumina의 연구 및 제품 개발 팀을 이끌고 있습니다. 이 팀은 Illumina의 혁신 엔진으로서, 차세대 시퀀싱 플랫폼 및 애플리케이션에서 우수한 제품을 제공하여 과학적 혁신과 유전체학의 임상 전환을 가속화합니다.

Barnard 박사는 1998년에 회사 최초의 과학자이자 네 번째 직원으로 Illumina에 합류했으며, 성공적인 25년간의 근속 기간 전체에 걸쳐 Illumina의 R&D 조직 내에서 다양한 리더십 직책을 맡았습니다. 연구 및 기술 개발 분야에서의 중요한 역할을 통해, Barnard 박사는 합성 화학, 단백질 공학, 표면 과학, assay 연구 및 나노 공정을 비롯한 Illumina의 기초 과학 기술을 성숙하게 만드는 데 상당한 기여를 했습니다. 그는 전 세계적으로 100개 이상의 특허를 보유하고 있으며 분석 화학, 자연, 과학 및 유전체 연구와 같은 다양한 업계 최고의 과학 저널에 발표되었습니다.

Barnard 박사는 혁신적인 NovaSeq X 시리즈의 출시 등 Illumina의 업계를 선도하는 제품을 발전시키는 일에서 중추적인 역할을 해 왔습니다. Illumina의 핵심 기술에 대한 그의 심도 깊은 이해는 R&D 생산성과 효율성을 가속화할 뿐만 아니라 주주 가치도 높이고 있습니다.

Todd Christian is Head of Services, Arrays, and Genomics Access (SAGA) at Illumina, where he is responsible for the go-to-market strategy and commercialization of arrays, pharma and clinical diagnostics partnerships, Population Genomics, Services and Support, and Illumina Lab Services.

Before joining Illumina, Christian was vice president and general manager of the cell analysis division at Agilent Technologies, Inc. During his time there, he was an integral part of the company’s multi-year growth strategy to expand its position in cell analysis and other high-growth segments of the life sciences, biopharma and diagnostics markets to serve new and existing customers.

Christian is a distinguished leader in the life sciences market, with more than 25 years of experience in the industry. Before joining Agilent, he spent a number of years at both large and small organizations in the life sciences space, including Becton Dickinson, Applied Bioscience, and Guava Technologies.

He holds a Bachelor of Arts from Hamilton College and a variety of executive certificate programs in marketing, program management, and operations. He has recently served on a variety of non-profit boards focused on funding youth education and underserved communities, and actively volunteers with Habitat for Humanity.

As Chief Legal Officer, Julie Coletti has worldwide responsibility for all legal, regulatory, and intellectual property matters; government affairs; and market access. She also serves as Corporate Secretary to the Illumina Board of Directors.

Prior to joining Illumina, Coletti was the Chief Legal and Regulatory Officer and Corporate Secretary at Align Technology, Inc. Before that, Coletti served as Vice President and Global General Counsel of Danaher Corporation’s Dental Platform and as Vice President of Bayer HealthCare and Chief Legal Officer/Corporate Secretary for the MEDRAD, Inc./Bayer Radiology and Interventional Division. 

Coletti brings extensive experience advising boards of directors and executive leaders on a broad range of complex issues, including M&A strategies, litigation, compliance matters, governance, and public policy. She is also recognized for building high-performing teams and fostering cultures of continuous learning, development, and positive change.

Coletti received her J.D. from the University of Pittsburgh and her B.A. in English from Rutgers University. Currently, she serves as an independent director for Fortis Life Sciences and a board member for the Humane Animal Rescue of Pittsburgh.

As Chief Financial Officer (CFO), Ankur Dhingra is responsible for Illumina’s accounting, financial planning and analysis, internal audit, investor relations, tax, and treasury functions.

Prior to joining Illumina, Dhingra served as CFO at Summit Therapeutics – a California-based biopharmaceutical oncology company. He was previously CFO at CareDx, Inc, a molecular diagnostics company focused on the transplant patient journey. Dhingra spent 18 years at Agilent Technologies in a variety of financial and operational leadership roles, including Vice President of Investor Relations and Group CFO for the Life Sciences and Applied Markets Group (LSAG), which consists of Agilent's market leading analytical instrument portfolio, informatics, and cell analysis franchise.

Mr. Dhingra is a Chartered Accountant from The Institute of Chartered Accountants of India.

Mark Field joined Illumina as Chief Information Officer on May 29, 2025, bringing over two decades of experience in leading transformative technology initiatives across the life sciences and healthcare sectors. Prior to this role, he served as Chief Technology Officer at Insulet Corporation, where he was instrumental in the development and launch of the Omnipod® 5, the first tubeless automated insulin delivery system. Under his leadership, Omnipod® 5 achieved significant market success, contributing to Insulet's annual revenue surpassing $2 billion and serving approximately 500,000 patients worldwide.

Before his tenure at Insulet, Field held the position of Chief Technology Officer at Thermo Fisher Scientific. There, he led a global team responsible for IoT-connected device programs, cloud-based scientific services, and e-commerce, overseeing 54 business units. He was pivotal in developing the Thermo Fisher Cloud, a platform that revolutionized data sharing among scientists globally. Field's career also includes 17 years at Oracle Corporation, where he rose to Vice President and successfully led the integration of over 105 acquisitions.

Field holds a Bachelor of Science in Computer Science and a Bachelor of Commerce in Management and Information Systems from the University of Auckland in New Zealand. His extensive experience in regulated medical technology environments and his commitment to patient-centric design make him a valuable addition to Illumina's leadership team. As CIO, Field is poised to drive Illumina's digital transformation efforts, leveraging his global perspective and innovative approach to technology to enhance operational excellence and market leadership.

Eric Green, MD, PhD, is the Chief Medical Officer (CMO) at Illumina. As Illumina’s medical leader, Dr. Green is responsible for guiding global efforts to advance the clinical application of genomics, expand access to precision medicine, and increase diversity in genomic data to improve healthcare for people worldwide.

Prior to joining Illumina, Dr. Green worked at the National Human Genome Research Institute (NHGRI) at the U.S. National Institutes of Health (NIH) for more than 31 years, serving as the NHGRI Director for his final 15 years. Under his leadership, NHGRI became a driving force in integrating genomics into medicine and public health. Before being appointed as the institute’s director, Dr. Green served multiple other leadership roles within NHGRI, including as the institute’s Scientific Director for nearly a decade and as the founding Director of the NIH Intramural Sequencing Center.

Throughout his multi-decade career, Dr. Green has consistently been at the forefront of genomics, helping transform the field from research-driven discovery to clinical practice. His research and leadership contributions have included playing a prominent role in the Human Genome Project, delivering critical insights into genome structure and function through comparative genomics, identifying multiple human disease genes, and accelerating applications of genomics in healthcare.

Dr. Green earned his MD and PhD from Washington University School of Medicine in 1987.

Pat Leckman은 Illumina의 최고 인사 책임자로서 회사의 HR 전략의 모든 측면을 담당합니다. Leckman은 인력 변혁을 주도하고, 비즈니스 성장을 추진하며, 영향력이 큰 팀을 창출한 성공적인 실적을 보유하고 있습니다.

이전에는 Watson Wyatt, NVIDIA, Cisco 및 Perot Systems와 같은 역동적인 조직에서 근무했습니다. 그녀는 Illumina 인사 리더십 팀의 일원으로 재직하면서 보상, 복리후생 및 피플 테크놀로지 기능을 변화시켰습니다. 그녀는 계약 및 합작투자를 설계, 계약 및 이행하는 국제 팀을 이끌었습니다. 경력 전반에 걸쳐 그녀는 비즈니스 프로세스 재설계, 벤더 평가, 아웃소싱 및 전환 관리를 통해 고객을 도왔습니다.

Leckman은 런던 경영대학원에서 경영학 석사 학위를, 스탠포드 대학에서 커뮤니케이션 학사 학위를 취득했습니다.

Rami Mehio is the Senior Vice President, General Manager, BioInsight at Illumina. He is responsible for leading the research and development teams for bioinformatics, software, clinical interpretation and AI, as well as managing data partnerships, pharma collaborations, and national genomics initiatives. These teams deliver industry-leading solutions for genomic and multiomic applications, working closely with partners and customers to build, analyze, and monetize large datasets—leveraging them to develop new AI models and advance deep biological insights.

Mehio joined Illumina in 2018 through the acquisition of Edico Genome, where he led the development of the DRAGEN™ Bio-IT platform. He would later serve as Vice President and Head of Software and Informatics, where he drove Illumina’s software and informatics strategy across the company’s entire product portfolio, include instruments, cloud data platforms, and bioinformatics solutions.

Since joining Illumina, Mehio has played a pivotal role in establishing the company’s informatics offering as a comprehensive, end-to-end suite, including DRAGEN, Emedgene, ICA, and ICI products. Other key highlights under his leadership including the development of the COVIDSeq test, processing 500,000 UK Biobank samples, winning the PrecisionFDA challenge, and supporting the launch of NovaSeq, NextSeq 2000, and iSeq 100 sequencers.

Mehio holds both a Master of Science and a Bachelor of Science in Engineering from McGill University, and holds 166 global patents.

Kevin Pegels는 Illumina의 글로벌 운영 책임자로서 회사의 글로벌 운영을 책임지고 있습니다. 그의 조직에는 높은 제품 품질과 고객 만족을 보장하기 위해 노력하는 제조, 공급망, 수명 주기 관리, 정보 기술 및 글로벌 시설 및 부동산 팀이 있습니다.

Illumina에 합류하기 전에, Kevin은 Bayer Healthcare, The Clorox Company 및 Levi Strauss의 공급망 및 운영 조직을 이끄는 고위 리더십 역할을 20년 이상 담당했습니다. 또한 그는 공급망, 경영 전략 및 프로세스 개선에 대해 회사에 자문을 하는 Deloitte Consulting에서 경력을 쌓았습니다.

Kevin은 현재 Bio Supply Management Alliance(BSMA)의 자문 위원회에서 활동하고 있으며, San Diego Regional EDC의 이사회에 합류할 예정입니다. 그는 Cornell University에서 화학공학 학사 학위를 취득했고, Harvard Business School에서 경영학 석사 학위를 취득했습니다.

As Chief Commercial Officer of Illumina, Michael Sullivan is responsible for leading the company’s global commercial organization.

Before joining Illumina, Sullivan was Chief Commercial Officer at Caris Life Sciences, where he oversaw global commercial strategy and operations across the company’s precision oncology portfolio. During his six-year tenure, he played a pivotal role in the company’s growth, helping drive revenue to approximately $1 billion annually and leading the expansion of Caris’ international footprint through strategic market entry initiatives, distributor partnerships, and regional infrastructure development. 

Prior to Caris, Sullivan held senior commercial leadership roles at Roche Diagnostics, Johnson & Johnson’s Ortho Clinical Diagnostics, IDEXX Laboratories, and Abbott Diagnostics. 

Throughout his career, Sullivan has led organizations through periods of growth and transformation, helping customers adopt innovative technologies and solutions. He has extensive experience building and scaling commercial functions, developing strategic partnerships, and catalyzing expansion across diagnostics and precision medicine businesses.

Sullivan earned a Bachelor of Business Administration in Marketing from Texas A&M University, where he participated in the Honors Program and played varsity football.

Jakob Wedel is Chief Strategy and Corporate Development Officer at Illumina, leading corporate strategy, partnerships, alliances, and acquisitions. With more than 25 years in top-tier strategy consulting focused on the life science and technology sector, Mr. Wedel brings a wealth of expertise in driving growth and innovation to the company.

Prior to joining Illumina, Wedel was a Senior Partner at Ernst and Young's strategy practice, EY Parthenon, where he played a key role in the global expansion of its life science strategy practice. His leadership in the global life science practice provided him with deep insights into the dynamics of the life science tools, clinical diagnostics and biopharma sectors, and positioned him as a trusted advisor for global industry executives.

Wedel spent more than 20 years at renowned consulting firms McKinsey and Bain & Co. serving life science, diagnostics and pharmaceutical clients in the US and Europe. He co-founded the Nordic strategy firm Qvartz, which grew to 450 professionals before being acquired by Bain.

Wedel attended Aarhus University in Denmark and earned a Master of Science in International Marketing & Management from Copenhagen Business School.

Conor McNamara, CFA, is Head of Investor Relations at Illumina, a role he assumed in September 2025.

Prior to joining Illumina, Conor was an Equity Research Analyst at RBC Capital Markets, where he covered the Life Science Tools & Diagnostics sector, including Illumina. From 2005 to 2021, he held analyst and portfolio manager roles at three investment firms – FrontPoint, Hudson Bay, and Tamarack – where he focused on the life sciences sector. Earlier in his career, Conor worked in investment banking and M&A advisory at Lehman Brothers and Deloitte, and in corporate development at McKesson.

Conor is a Chartered Financial Analyst (CFA) and holds a Bachelor of Arts degree in Economics from Occidental College.